Connect Biopharma Holdings (CNTB) Research & Development (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Research & Development for 3 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 126.59% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.2 million (up 69.67% YoY) and the FY2025 annual result came in at $37.8 million, up 29.2% from the prior year.
• Research & Development climbed to $15.0 million in Q1 2026 per CNTB's latest filing, from $11.3 million in the prior quarter.
• Over the last five years, Research & Development for CNTB reached as high as $15.0 million in Q1 2026 and fell as low as $5.3 million in Q2 2024.
• A 3-year average of $9.1 million and a median of $8.8 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2025 — Research & Development declined 23.43% — and 2026, when it jumped 126.59%.
• Year by year, Research & Development stood at $6.2 million in 2024, then soared by 80.92% to $11.3 million in 2025, then soared by 33.22% to $15.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.0 million, $11.3 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.